Top

Published in:

Open Access 01-12-2015 | Review

Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications

Authors: Rebecca Kohnken, Karthik M. Kodigepalli, Li Wu

Published in: Molecular Cancer | Issue 1/2015

Abstract

Regulation of intracellular deoxynucleoside triphosphate (dNTP) pool is critical to genomic stability and cancer development. Imbalanced dNTP pools can lead to enhanced mutagenesis and cell proliferation resulting in cancer development. Therapeutic agents that target dNTP synthesis and metabolism are commonly used in treatment of several types of cancer. Despite several studies, the molecular mechanisms that regulate the intracellular dNTP levels and maintain their homeostasis are not completely understood. The discovery of SAMHD1 as the first mammalian dNTP triphosphohydrolase provided new insight into the mechanisms of dNTP regulation. SAMHD1 maintains the homeostatic dNTP levels that regulate DNA replication and damage repair. Recent progress indicates that gene mutations and epigenetic mechanisms lead to downregulation of SAMHD1 activity or expression in multiple cancers. Impaired SAMHD1 function can cause increased dNTP pool resulting in genomic instability and cell-cycle progression, thereby facilitating cancer cell proliferation. This review summarizes the latest advances in understanding the importance of dNTP metabolism in cancer development and the novel function of SAMHD1 in regulating this process.

Kunz BA, Kohalmi SE, Kunkel TA, Mathews CK, McIntosh EM, Reidy JA. International Commission for Protection Against Environmental Mutagens and Carcinogens. Deoxyribonucleoside triphosphate levels: a critical factor in the maintenance of genetic stability. Mutat Res. 1994;318(1):1–64.CrossRefPubMed

Reichard P. Interactions between deoxyribonucleotide and DNA synthesis. Annu Rev Biochem. 1988;57:349–74. doi:10.1146/annurev.bi.57.070188.002025.CrossRefPubMed

Aird KM, Zhang R. Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett. 2015;356(2 Pt A):204–10. doi:10.1016/j.canlet.2014.01.017.CrossRefPubMed

Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol. 2002;3(7):415–24.CrossRefPubMed

Hrecka K, Hao C, Gierszewska M, Swanson SK, Kesik-Brodacka M, Srivastava S, et al. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature. 2011;474(7353):658–61. doi:10.1038/nature10195.PubMedCentralCrossRefPubMed

Laguette N, Sobhian B, Casartelli N, Ringeard M, Chable-Bessia C, Segeral E, et al. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature. 2011;474(7353):654–7. doi:10.1038/nature10117.PubMedCentralCrossRefPubMed

Powell RD, Holland PJ, Hollis T, Perrino FW. Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem. 2011;286(51):43596–600. doi:10.1074/jbc.C111.317628.PubMedCentralCrossRefPubMed

Goldstone DC, Ennis-Adeniran V, Hedden JJ, Groom HC, Rice GI, Christodoulou E, et al. HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature. 2011;480(7377):379–82. doi:10.1038/nature10623.CrossRefPubMed

Lahouassa H, Daddacha W, Hofmann H, Ayinde D, Logue EC, Dragin L, et al. SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol. 2012;13(3):223–8. doi:10.1038/ni.2236.PubMedCentralCrossRefPubMed

10.

Rice GI, Bond J, Asipu A, Brunette RL, Manfield IW, Carr IM, et al. Mutations involved in Aicardi-Goutieres syndrome implicate SAMHD1 as regulator of the innate immune response. Nat Genet. 2009;41(7):829–32. doi:10.1038/ng.373.PubMedCentralCrossRefPubMed

11.

Clifford R, Louis T, Robbe P, Ackroyd S, Burns A, Timbs AT, et al. SAMHD1 is mutated recurrently in chronic lymphocytic leukemia and is involved in response to DNA damage. Blood. 2014;123(7):1021–31. doi:10.1182/blood-2013-04-490847.PubMedCentralCrossRefPubMed

12.

Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–6. doi:10.1126/science.1164368.PubMedCentralCrossRefPubMed

13.

Landau DA, Carter SL, Stojanov P, McKenna A, Stevenson K, Lawrence MS, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013;152(4):714–26. doi:10.1016/j.cell.2013.01.019.PubMedCentralCrossRefPubMed

14.

Liu J, Lee W, Jiang Z, Chen Z, Jhunjhunwala S, Haverty PM, et al. Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events. Genome Res. 2012;22(12):2315–27. doi:10.1101/gr.140988.112.PubMedCentralCrossRefPubMed

15.

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807–12. doi:10.1126/science.1164382.PubMedCentralCrossRefPubMed

16.

Schuh A, Becq J, Humphray S, Alexa A, Burns A, Clifford R, et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood. 2012;120(20):4191–6. doi:10.1182/blood-2012-05-433540.CrossRefPubMed

17.

Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006;314(5797):268–74. doi:10.1126/science.1133427.CrossRefPubMed

18.

Walker BA, Wardell CP, Melchor L, Hulkki S, Potter NE, Johnson DC, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012;120(5):1077–86. doi:10.1182/blood-2012-03-412981.CrossRefPubMed

19.

Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012;488(7413):660–4. doi:10.1038/nature11282.PubMedCentralCrossRefPubMed

20.

de Silva S, Wang F, Hake TS, Porcu P, Wong HK, Wu L. Downregulation of SAMHD1 expression correlates with promoter DNA methylation in Sezary syndrome patients. J Invest Dermatol. 2014;134(2):562–5. doi:10.1038/jid.2013.311.PubMedCentralCrossRefPubMed

21.

Wang JL, Lu FZ, Shen XY, Wu Y, Zhao LT. SAMHD1 is down regulated in lung cancer by methylation and inhibits tumor cell proliferation. Biochem Biophys Res Commun. 2014;455(3-4):229–33. doi:10.1016/j.bbrc.2014.10.153.CrossRefPubMed

22.

Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145(3):435–46. doi:10.1016/j.cell.2011.03.044.PubMedCentralCrossRefPubMed

23.

Ji X, Wu Y, Yan J, Mehrens J, Yang H, DeLucia M, et al. Mechanism of allosteric activation of SAMHD1 by dGTP. Nat Struct Mol Biol. 2013;20(11):1304–9. doi:10.1038/nsmb.2692.CrossRefPubMed

24.

Rampazzo C, Miazzi C, Franzolin E, Pontarin G, Ferraro P, Frangini M, et al. Regulation by degradation, a cellular defense against deoxyribonucleotide pool imbalances. Mutat Res. 2010;703(1):2–10. doi:10.1016/j.mrgentox.2010.06.002.CrossRefPubMed

25.

Kretschmer S, Wolf C, Konig N, Staroske W, Guck J, Hausler M, et al. SAMHD1 prevents autoimmunity by maintaining genome stability. Ann Rheum Dis. 2015;74(3):e17. doi:10.1136/annrheumdis-2013-204845.PubMedCentralCrossRefPubMed

26.

Aye Y, Li M, Long MJ, Weiss RS. Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. Oncogene. 2015;34(16):2011–21. doi:10.1038/onc.2014.155.CrossRefPubMed

27.

Gandhi VV, Samuels DC. A review comparing deoxyribonucleoside triphosphate (dNTP) concentrations in the mitochondrial and cytoplasmic compartments of normal and transformed cells. Nucleosides Nucleotides Nucleic Acids. 2011;30(5):317–39. doi:10.1080/15257770.2011.586955.PubMedCentralCrossRefPubMed

28.

Loeb LA. A mutator phenotype in cancer. Cancer Res. 2001;61(8):3230–9.PubMed

29.

Venkatesan RN, Bielas JH, Loeb LA. Generation of mutator mutants during carcinogenesis. DNA Repair (Amst). 2006;5(3):294–302. doi:10.1016/j.dnarep.2005.10.012.CrossRef

30.

Niida H, Shimada M, Murakami H, Nakanishi M. Mechanisms of dNTP supply that play an essential role in maintaining genome integrity in eukaryotic cells. Cancer Sci. 2010;101(12):2505–9. doi:10.1111/j.1349-7006.2010.01719.x.CrossRefPubMed

31.

Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005;434(7035):864–70. doi:10.1038/nature03482.CrossRefPubMed

32.

Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434(7035):907–13. doi:10.1038/nature03485.CrossRefPubMed

33.

Chen W, Zhang L, Zhang K, Zhou B, Kuo ML, Hu S, et al. Reciprocal regulation of autophagy and dNTP pools in human cancer cells. Autophagy. 2014;10(7):1272–84. doi:10.4161/auto.28954.PubMedCentralCrossRefPubMed

34.

Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003;3(5):330–8. doi:10.1038/nrc1074.CrossRefPubMed

35.

Ewald B, Sampath D, Plunkett W. Nucleoside analogs: molecular mechanisms signaling cell death. Oncogene. 2008;27(50):6522–37. doi:10.1038/onc.2008.316.CrossRefPubMed

36.

Yoshio N, Kawai Y, Hori H, Ueda T. Resistance to 9-beta-D-arabinofuranosyl-2-fluoroadenine due to reduced incorporation into DNA from competition by excess deoxyadenosine triphosphate: implications for different sensitivities to nucleoside analogues. Int J Hematol. 2005;81(5):405–12.CrossRefPubMed

37.

Ballana E, Badia R, Terradas G, Torres-Torronteras J, Ruiz A, Pauls E, et al. SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors. Antimicrob Agents Chemother. 2014;58(8):4804–13. doi:10.1128/AAC.03145-14.PubMedCentralCrossRefPubMed

38.

Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, et al. SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med. 2012;18(11):1682–7. doi:10.1038/nm.2964.CrossRefPubMed

39.

St Gelais C, de Silva S, Amie SM, Coleman CM, Hoy H, Hollenbaugh JA, et al. SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. Retrovirology. 2012;9:105. doi:10.1186/1742-4690-9-105.PubMedCentralCrossRefPubMed

40.

Franzolin E, Pontarin G, Rampazzo C, Miazzi C, Ferraro P, Palumbo E, et al. The deoxynucleotide triphosphohydrolase SAMHD1 is a major regulator of DNA precursor pools in mammalian cells. Proc Natl Acad Sci U S A. 2013;110(35):14272–7. doi:10.1073/pnas.1312033110.PubMedCentralCrossRefPubMed

41.

Nordlund P, Reichard P. Ribonucleotide reductases. Annu Rev Biochem. 2006;75:681–706. doi:10.1146/annurev.biochem.75.103004.142443.CrossRefPubMed

42.

Zhu C, Gao W, Zhao K, Qin X, Zhang Y, Peng X, et al. Structural insight into dGTP-dependent activation of tetrameric SAMHD1 deoxynucleoside triphosphate triphosphohydrolase. Nat Commun. 2013;4:2722. doi:10.1038/ncomms3722.PubMed

43.

Ji X, Tang C, Zhao Q, Wang W, Xiong Y. Structural basis of cellular dNTP regulation by SAMHD1. Proc Natl Acad Sci U S A. 2014;111(41):E4305–14. doi:10.1073/pnas.1412289111.PubMedCentralCrossRefPubMed

44.

Gramberg T, Kahle T, Bloch N, Wittmann S, Mullers E, Daddacha W, et al. Restriction of diverse retroviruses by SAMHD1. Retrovirology. 2013;10:26. doi:10.1186/1742-4690-10-26.PubMedCentralCrossRefPubMed

45.

Kim ET, White TE, Brandariz-Nunez A, Diaz-Griffero F, Weitzman MD. SAMHD1 restricts herpes simplex virus 1 in macrophages by limiting DNA replication. J Virol. 2013;87(23):12949–56. doi:10.1128/JVI.02291-13.PubMedCentralCrossRefPubMed

46.

Chen Z, Zhu M, Pan X, Zhu Y, Yan H, Jiang T, et al. Inhibition of Hepatitis B virus replication by SAMHD1. Biochem Biophys Res Commun. 2014;450(4):1462–8. doi:10.1016/j.bbrc.2014.07.023.CrossRefPubMed

47.

Cribier A, Descours B, Valadao AL, Laguette N, Benkirane M. Phosphorylation of SAMHD1 by cyclin A2/CDK1 regulates its restriction activity toward HIV-1. Cell Rep. 2013;3(4):1036–43. doi:10.1016/j.celrep.2013.03.017.CrossRefPubMed

48.

White TE, Brandariz-Nunez A, Valle-Casuso JC, Amie S, Nguyen LA, Kim B, et al. The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe. 2013;13(4):441–51. doi:10.1016/j.chom.2013.03.005.CrossRefPubMed

49.

St Gelais C, de Silva S, Hach JC, White TE, Diaz-Griffero F, Yount JS, et al. Identification of cellular proteins interacting with the retroviral restriction factor SAMHD1. J Virol. 2014;88(10):5834–44. doi:10.1128/JVI.00155-14.PubMedCentralCrossRefPubMed

50.

Pauls E, Ruiz A, Badia R, Permanyer M, Gubern A, Riveira-Munoz E, et al. Cell cycle control and HIV-1 susceptibility are linked by CDK6-dependent CDK2 phosphorylation of SAMHD1 in myeloid and lymphoid cells. J Immunol. 2014;193(4):1988–97. doi:10.4049/jimmunol.1400873.CrossRefPubMed

51.

Pauls E, Ruiz A, Riveira-Munoz E, Permanyer M, Badia R, Clotet B, et al. p21 regulates the HIV-1 restriction factor SAMHD1. Proc Natl Acad Sci U S A. 2014;111(14):E1322–4. doi:10.1073/pnas.1322059111.PubMedCentralCrossRefPubMed

52.

Kyei GB, Cheng X, Ramani R, Ratner L. Cyclin L2 is a critical HIV dependency factor in macrophages that controls SAMHD1 abundance. Cell Host Microbe. 2015;17(1):98–106. doi:10.1016/j.chom.2014.11.009.CrossRefPubMed

53.

Behrendt R, Schumann T, Gerbaulet A, Nguyen LA, Schubert N, Alexopoulou D, et al. Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response. Cell Rep. 2013;4(4):689–96. doi:10.1016/j.celrep.2013.07.037.CrossRefPubMed

54.

Goutieres F. Aicardi-Goutieres syndrome. Brain Dev. 2005;27(3):201–6. doi:10.1016/j.braindev.2003.12.011.CrossRefPubMed

55.

Lee-Kirsch MA. Nucleic acid metabolism and systemic autoimmunity revisited. Arthritis Rheum. 2010;62(5):1208–12. doi:10.1002/art.27372.CrossRefPubMed

56.

Leshinsky-Silver E, Malinger G, Ben-Sira L, Kidron D, Cohen S, Inbar S, et al. A large homozygous deletion in the SAMHD1 gene causes atypical Aicardi-Goutieres syndrome associated with mtDNA deletions. Eur J Hum Genet. 2011;19(3):287–92. doi:10.1038/ejhg.2010.213.PubMedCentralCrossRefPubMed

57.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. doi:10.1016/j.cell.2011.02.013.CrossRefPubMed

58.

Network CGA. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330–7. doi:10.1038/nature11252.CrossRef

59.

Rehwinkel J, Maelfait J, Bridgeman A, Rigby R, Hayward B, Liberatore RA, et al. SAMHD1-dependent retroviral control and escape in mice. EMBO J. 2013;32(18):2454–62. doi:10.1038/emboj.2013.163.PubMedCentralCrossRefPubMed

60.

Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). Br J Haematol. 2011;155(2):150–66. doi:10.1111/j.1365-2141.2011.08852.x.PubMedCentralCrossRefPubMed

61.

Baylin SB, Jones PA. A decade of exploring the cancer epigenome - biological and translational implications. Nat Rev Cancer. 2011;11(10):726–34. doi:10.1038/nrc3130.PubMedCentralCrossRefPubMed

62.

Hagelkruys A, Sawicka A, Rennmayr M, Seiser C. The biology of HDAC in cancer: the nuclear and epigenetic components. Handb Exp Pharmacol. 2011;206:13–37. doi:10.1007/978-3-642-21631-2_2.CrossRefPubMed

63.

de Silva S, Hoy H, Hake TS, Wong HK, Porcu P, Wu L. Promoter methylation regulates SAMHD1 gene expression in human CD4+ T cells. J Biol Chem. 2013;288(13):9284–92. doi:10.1074/jbc.M112.447201.PubMedCentralCrossRefPubMed

64.

Jin C, Peng X, Liu F, Cheng L, Lu X, Yao H, et al. MicroRNA-181 expression regulates specific post-transcriptional level of SAMHD1 expression in vitro. Biochem Biophys Res Commun. 2014;452(3):760–7. doi:10.1016/j.bbrc.2014.08.151.CrossRefPubMed

65.

Zhao K, Du J, Han X, Goodier JL, Li P, Zhou X, et al. Modulation of LINE-1 and Alu/SVA retrotransposition by Aicardi-Goutieres syndrome-related SAMHD1. Cell Rep. 2013;4(6):1108–15. doi:10.1016/j.celrep.2013.08.019.PubMedCentralCrossRefPubMed

66.

Kumar D, Viberg J, Nilsson AK, Chabes A. Highly mutagenic and severely imbalanced dNTP pools can escape detection by the S-phase checkpoint. Nucleic Acids Res. 2010;38(12):3975–83. doi:10.1093/nar/gkq128.PubMedCentralCrossRefPubMed

67.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4. doi:10.1158/2159-8290.CD-12-0095.CrossRefPubMed

68.

Wu L. Cellular and Biochemical Mechanisms of the Retroviral Restriction Factor SAMHD1. ISRN Biochem. 2013;2013. doi:10.1155/2013/728392.

Title: Regulation of deoxynucleotide metabolism in cancer: novel mechanisms and therapeutic implications
Authors: Rebecca Kohnken
Karthik M. Kodigepalli
Li Wu
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2015
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/s12943-015-0446-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells

Human papillomavirus mediated inhibition of DNA damage sensing and repair drives skin carcinogenesis

RUNX2 and the PI3K/AKT axis reciprocal activation as a driving force for tumor progression

Stratifin accelerates progression of lung adenocarcinoma at an early stage

Dioxin receptor regulates aldehyde dehydrogenase to block melanoma tumorigenesis and metastasis

Aberrant regulation of the LIN28A/LIN28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer